Inflammatory activity and vitamin D levels in an MS population treated with rituximab [0.03%]
利妥昔单抗治疗多发性硬化症患者的炎症作用和维生素D水平
Johan Linden,Gabriel Granåsen,Jonatan Salzer et al.
Johan Linden et al.
Background: Most multiple sclerosis patients on disease-modifying treatment at Umeå University Hospital are treated with rituximab and the prevalence of vitamin D supplementation has increased over time. Follow-up studie...
Effect of different doses of gadolinium contrast agent on clinical outcomes in MS [0.03%]
不同剂量的钆对比剂对多发性硬化症患者临床结局的影响
Nathalie Ackermans,Carolyn Taylor,Roger Tam et al.
Nathalie Ackermans et al.
Objective: The objective of this paper is to evaluate potential dose-dependent adverse effects of gadolinium-based contrast agents (GBCAs) on MS progression. ...
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy [0.03%]
克拉屈滨治疗复发的多发性硬化症患者转换为特立氟胺治疗后的病情缓解：特立氟胺治疗的12个月中期结果
Stanley L Cohan,Keith Edwards,Lindsay Lucas et al.
Stanley L Cohan et al.
Background: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies. ...
Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease? [0.03%]
进行性单灶性硬化症的高级影像学表现：是单一病灶还是全身性疾病？
Lisa Eunyoung Lee,Jillian K Chan,Emilie Nevill et al.
Lisa Eunyoung Lee et al.
Background: Progressive solitary sclerosis is a unifocal demyelinating disease recently proposed as a possible multiple sclerosis variant. Objective: ...
Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results [0.03%]
由非聚乙二醇化干扰素β-1a转为聚乙二醇化干扰素β-1a的患者新发流感样症状的风险较低：ALLOW三期临床试验结果
Robert T Naismith,Barry Hendin,Sibyl Wray et al.
Robert T Naismith et al.
Background: Flu-like symptoms are common adverse events associated with interferon beta relapsing multiple sclerosis therapies. Objectives: ...
Cognitive function predicts work disability among multiple sclerosis patients [0.03%]
认知功能可预测多发性硬化患者的劳动能力受损状况
Andrius Kavaliunas,Petter Tinghög,Emilie Friberg et al.
Andrius Kavaliunas et al.
Background: In multiple sclerosis various aspects of cognitive function can be detrimentally affected. More than that, patients´ employment and social functioning is likely to be impacted. ...
The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod [0.03%]
FLUENT研究设计：调查氟西洛莫德治疗复发性多发性硬化症患者亚群和神经丝的变化
Jeffrey A Cohen,Amit Bar-Or,Bruce A C Cree et al.
Jeffrey A Cohen et al.
Background: Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of patients with relapsing forms of multiple sclerosis (RMS). Fingolimod sequesters lymphocytes within lymphoid tissue thereby reduc...
Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis [0.03%]
髓鞘脱髓鞘疾病患者脑脊液中的接触蛋白-1和接触蛋白-2作为轴突病理的生物标志物
Madhurima Chatterjee,Marleen Ja Koel-Simmelink,Inge Mw Verberk et al.
Madhurima Chatterjee et al.
Background: Contactin-1 and contactin-2 are important for the maintenance of axonal integrity. Objective: To investigate the cerebrospi...
A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis [0.03%]
奥仑珠单抗治疗多发性硬化后的自身免疫性肌炎病例报告
Patrick Aouad,Con Yiannikas,Suran L Fernando et al.
Patrick Aouad et al.
Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occ...
A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs [0.03%]
一种新药与干扰素β-1A注射液头对头对比：在真实世界中比较多发性硬化症患者复发率、医疗保健成本和资源使用情况
James D Bowen,Chris M Kozma,Megan M Grosso et al.
James D Bowen et al.
Background: Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings. Objecti...